Emerging World Pharma Stock Net Income
| EWPI Stock | USD 0.0001 0.00 0.00% |
Emerging World Pharma technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Emerging World's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Emerging World's valuation are provided below:Market Capitalization 11.9 K | Earnings Share (0) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -369.3 K | -350.8 K | |
| Net Loss | -369.3 K | -350.8 K | |
| Net Loss | -369.3 K | -350.8 K |
Emerging | Net Income | Build AI portfolio with Emerging Stock |
Latest Emerging World's Net Income Growth Pattern
Below is the plot of the Net Income of Emerging World Pharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Emerging World Pharma financial statement analysis. It represents the amount of money remaining after all of Emerging World Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Emerging World's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Emerging World's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (410.32 K) | 10 Years Trend |
|
Net Income |
| Timeline |
Emerging Net Income Regression Statistics
| Arithmetic Mean | (380,282) | |
| Coefficient Of Variation | (26.13) | |
| Mean Deviation | 49,468 | |
| Median | (410,316) | |
| Standard Deviation | 99,382 | |
| Sample Variance | 9.9B | |
| Range | 410K | |
| R-Value | (0.31) | |
| Mean Square Error | 9.5B | |
| R-Squared | 0.1 | |
| Significance | 0.22 | |
| Slope | (6,170) | |
| Total Sum of Squares | 158B |
Emerging Net Income History
Other Fundumenentals of Emerging World Pharma
Emerging World Net Income component correlations
Click cells to compare fundamentals
Is Drug Manufacturers - Specialty & Generic space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emerging World. If investors know Emerging will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emerging World listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0) |
The market value of Emerging World Pharma is measured differently than its book value, which is the value of Emerging that is recorded on the company's balance sheet. Investors also form their own opinion of Emerging World's value that differs from its market value or its book value, called intrinsic value, which is Emerging World's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emerging World's market value can be influenced by many factors that don't directly affect Emerging World's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emerging World's value and its price as these two are different measures arrived at by different means. Investors typically determine if Emerging World is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emerging World's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Emerging World 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Emerging World's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Emerging World.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Emerging World on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Emerging World Pharma or generate 0.0% return on investment in Emerging World over 90 days. Emerging World Pharma, Inc. invests in generic based pharmaceutical companies manufacturing within developing nations More
Emerging World Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Emerging World's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Emerging World Pharma upside and downside potential and time the market with a certain degree of confidence.
Emerging World Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Emerging World's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Emerging World's standard deviation. In reality, there are many statistical measures that can use Emerging World historical prices to predict the future Emerging World's volatility.Emerging World Pharma Backtested Returns
We have found three technical indicators for Emerging World Pharma, which you can use to evaluate the volatility of the firm. The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Emerging World are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Emerging World Pharma has perfect predictability. Overlapping area represents the amount of predictability between Emerging World time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Emerging World Pharma price movement. The serial correlation of 1.0 indicates that 100.0% of current Emerging World price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Emerging Operating Income
Operating Income |
|
Based on the recorded statements, Emerging World Pharma reported net income of (410,316). This is 100.12% lower than that of the Healthcare sector and 99.89% lower than that of the Drug Manufacturers - Specialty & Generic industry. The net income for all United States stocks is 100.07% higher than that of the company.
Emerging Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emerging World's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Emerging World could also be used in its relative valuation, which is a method of valuing Emerging World by comparing valuation metrics of similar companies.Emerging World is currently under evaluation in net income category among its peers.
Emerging Fundamentals
| Current Valuation | 2.15 M | ||||
| Shares Outstanding | 119.3 M | ||||
| Net Income | (410.32 K) | ||||
| Cash And Equivalents | 118.42 K | ||||
| Total Debt | 3.2 M | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (138.59 K) | ||||
| Earnings Per Share | (0) X | ||||
| Beta | 529.63 | ||||
| Market Capitalization | 11.9 K | ||||
| Total Asset | 2.71 M | ||||
| Retained Earnings | (1.71 M) | ||||
| Working Capital | (4.07 M) | ||||
| Current Liabilities | 4.07 M | ||||
| Net Asset | 2.71 M |
About Emerging World Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emerging World Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emerging World using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emerging World Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Emerging World Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Emerging World's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Emerging World Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Emerging World Pharma Stock:Check out Emerging World Piotroski F Score and Emerging World Altman Z Score analysis. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Drug Manufacturers - Specialty & Generic space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emerging World. If investors know Emerging will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emerging World listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0) |
The market value of Emerging World Pharma is measured differently than its book value, which is the value of Emerging that is recorded on the company's balance sheet. Investors also form their own opinion of Emerging World's value that differs from its market value or its book value, called intrinsic value, which is Emerging World's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emerging World's market value can be influenced by many factors that don't directly affect Emerging World's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emerging World's value and its price as these two are different measures arrived at by different means. Investors typically determine if Emerging World is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emerging World's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.